StockData

Genelux vs Lyell Immunopharma

GNLX and LYEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GNLX and LYEL compare

Lyell Immunopharma is the larger company, worth 3.7 times as much as Genelux ($335M against $90.5M).

Lyell Immunopharma scores higher on the StockData Score (6 against 5 for Genelux), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGNLXLYEL
Size and price
Market cap$90.5M$335M
Share price$2.00$13.67
Change, 1 year−62.4%−19.3%
Change, 5 years–−92.7%
Beta (5Y)0.731.37
StockData Score
Total score56 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/S–12407×
P/B5.6×1.4× (better)
FCF yield−31.7% (better)−40.0%
Growth
Revenue growth (TTM)–−55.0%
Revenue growth, 5Y average–−65.9%
Profitability
Operating margin–−949981%
Net margin–−920285%
FCF margin–−496189%
Return on equity−178%−93.3% (better)
Return on invested capital–−782%
Financial health
Debt / equity0.000.00
Current ratio2.395.36 (better)
Altman Z-score−14.83−7.05 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield−20.8%–
Shareholder yield−20.8%0.00% (better)
Ownership
Held by institutions21.7%48.9%
Held by insiders7.7%45.0%
Insider net buying, 12 months−$341K$74.4M (better)
Short interest, % of float10.9%10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.